The use of novel agents in the treatment of relapsed and refractory multiple myeloma

被引：63

作者：

Laubach, J. P. ^{[1
]}

Mahindra, A. ^{[2
]}

Mitsiades, C. S. ^{[1
]}

Schlossman, R. L. ^{[1
]}

Munshi, N. C. ^{[1
]}

Ghobrial, I. M. ^{[1
]}

Carreau, N. ^{[1
]}

Hideshima, T. ^{[1
]}

Anderson, K. C. ^{[1
]}

Richardson, P. G. ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Cleveland Clin, Taussig Canc Ctr, Dept Med Oncol, Cleveland, OH 44106 USA

来源：

LEUKEMIA | 2009年 / 23卷 / 12期

关键词：

multiple myeloma; chemotherapy; lenalidomide; thalidomide; bortezomib; PROTEASOME INHIBITOR PS-341; LENALIDOMIDE PLUS DEXAMETHASONE; PEGYLATED LIPOSOMAL DOXORUBICIN; HISTONE DEACETYLASE INHIBITION; BONE-MARROW-TRANSPLANTATION; PREVIOUSLY TREATED PATIENTS; OVERCOMES DRUG-RESISTANCE; LOW-DOSE THALIDOMIDE; EXTENDED FOLLOW-UP; PHASE-II;

D O I：

10.1038/leu.2009.179

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, the disease remains incurable and even patients who respond well to induction therapy ultimately relapse and require additional treatment. Conventional chemotherapy and high-dose therapy with stem cell transplantation (SCT) have historically been utilized in the management of relapsed MM, but in recent years the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, as well as the proteasome inhibitor bortezomib, have assumed a primary role in this setting. This review focuses on the role of thalidomide, lenalidomide and bortezomib in relapsed and refractory MM, with additional discussion dedicated to emerging drugs in relapsed MM that may prove beneficial to patients with this disease. Leukemia (2009) 23, 2222-2232; doi:10.1038/leu.2009.179; published online 10 September 2009

引用

页码：2222 / 2232

页数：11

共 126 条

[1] ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8
[2] Thalidomide and dexamethasone for resistant multiple myeloma
Anagnostopoulos, A
Weber, D
Rankin, K
Delasalle, K
Alexanian, R
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (05) : 768 - 771
[3] VAD CHEMOTHERAPY AS REMISSION INDUCTION FOR MULTIPLE-MYELOMA
ANDERSON, H
SCARFFE, JH
RANSON, M
YOUNG, R
WIERINGA, GS
MORGENSTERN, GR
FITZSIMMONS, L
RYDER, D
[J]. BRITISH JOURNAL OF CANCER, 1995, 71 (02) : 326 - 330
[4] Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature
Badros, Ashraf
Goloubeva, Olga
Dalai, Jay S.
Can, Llyas
Thompson, Jennifer
Rapoport, Aaron P.
Heyman, Meyer
Akpek, Gorgon
Fenton, Robert G.
[J]. CANCER, 2007, 110 (05) : 1042 - 1049
[5] BARLOGIE B, 1987, BLOOD, V70, P869
[6] BARLOGIE B, 1986, BLOOD, V67, P1298
[7] Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
Barlogie, B
Desikan, R
Eddlemon, P
Spencer, T
Zeldis, J
Munshi, N
Badros, A
Zangari, M
Anaissie, E
Epstein, J
Shaughnessy, J
Ayers, D
Spoon, D
Tricot, G
[J]. BLOOD, 2001, 98 (02) : 492 - 494
[8] EFFECTIVE TREATMENT OF ADVANCED MULTIPLE-MYELOMA REFRACTORY TO ALKYLATING-AGENTS
BARLOGIE, B
SMITH, L
ALEXANIAN, R
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (21) : 1353 - 1356
[9] Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin
Biehn, Suzanne E.
Moore, Dominic T.
Voorhees, Peter M.
Garcia, Reynaldo A.
Lehman, Mary Jo
Dees, E. Claire
Orlowski, Robert Z.
[J]. ANNALS OF HEMATOLOGY, 2007, 86 (03) : 211 - 216
[10] Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x

← 1 2 3 4 5 6 7 8 9 10 →